Literature DB >> 25752266

Analysis of repeated low-dose challenge studies.

Tracy L Nolen1, Michael G Hudgens, Pranab K Senb, Gary G Koch.   

Abstract

Preclinical evaluation of candidate human immunodeficiency virus (HIV) vaccines entails challenge studies whereby non-human primates such as macaques are vaccinated with either an active or control vaccine and then challenged (exposed) with a simian-version of HIV. Repeated low-dose challenge (RLC) studies in which each macaque is challenged multiple times (either until infection or some maximum number of challenges is reached) are becoming more common in an effort to mimic natural exposure to HIV in humans. Statistical methods typically employed for the testing for a vaccine effect in RLC studies include a modified version of Fisher's exact test as well as large sample approaches such as the usual log-rank test. Unfortunately, these methods are not guaranteed to provide a valid test for the effect of vaccination. On the other hand, valid tests for vaccine effect such as the exact log-rank test may not be easy to implement using software available to many researchers. This paper details which statistical approaches are appropriate for the analysis of RLC studies, and how to implement these methods easily in SAS or R.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  HIV; macaque; permutation test; pre-clinical studies; randomization inference; vaccine

Mesh:

Substances:

Year:  2015        PMID: 25752266      PMCID: PMC4420691          DOI: 10.1002/sim.6462

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  18 in total

1.  On the use of indicator variables for studying the time-dependence of parameters in a response-time model.

Authors:  C C Brown
Journal:  Biometrics       Date:  1975-12       Impact factor: 2.571

Review 2.  HIV vaccine design: insights from live attenuated SIV vaccines.

Authors:  Wayne C Koff; Philip R Johnson; David I Watkins; Dennis R Burton; Jeffrey D Lifson; Kim J Hasenkrug; Adrian B McDermott; Alan Schultz; Timothy J Zamb; Rosanne Boyle; Ronald C Desrosiers
Journal:  Nat Immunol       Date:  2006-01       Impact factor: 25.606

3.  HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges.

Authors:  Dennis Ellenberger; Ronald A Otten; Bin Li; Michael Aidoo; I Vanessa Rodriguez; Carlos A Sariol; Melween Martinez; Michael Monsour; Linda Wyatt; Michael G Hudgens; Edmundo Kraiselburd; Bernard Moss; Harriet Robinson; Thomas Folks; Salvatore Butera
Journal:  Virology       Date:  2006-05-24       Impact factor: 3.616

Review 4.  Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective.

Authors:  Silvija I Staprans; Mark B Feinberg; John W Shiver; Danilo R Casimiro
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

5.  Practical implications of modes of statistical inference for causal effects and the critical role of the assignment mechanism.

Authors:  D B Rubin
Journal:  Biometrics       Date:  1991-12       Impact factor: 2.571

Review 6.  Biostatistical implications of design, sampling, and measurement to health science data analysis.

Authors:  G G Koch; D B Gillings; M E Stokes
Journal:  Annu Rev Public Health       Date:  1980       Impact factor: 21.981

7.  Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA.

Authors: 
Journal:  AIDS       Date:  2007-02-19       Impact factor: 4.177

8.  Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates.

Authors:  Adrian B McDermott; Jacque Mitchen; Shari Piaskowski; Ivna De Souza; Levi J Yant; Jason Stephany; Jessica Furlott; David I Watkins
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

9.  Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.

Authors:  Roland R Regoes; Ira M Longini; Mark B Feinberg; Silvija I Staprans
Journal:  PLoS Med       Date:  2005-07-19       Impact factor: 11.069

10.  Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir.

Authors:  J Gerardo García-Lerma; Ron A Otten; Shoukat H Qari; Eddie Jackson; Mian-Er Cong; Silvina Masciotra; Wei Luo; Caryn Kim; Debra R Adams; Michael Monsour; Jonathan Lipscomb; Jeffrey A Johnson; David Delinsky; Raymond F Schinazi; Robert Janssen; Thomas M Folks; Walid Heneine
Journal:  PLoS Med       Date:  2008-02       Impact factor: 11.069

View more
  8 in total

1.  A Depot Medroxyprogesterone Acetate Dose That Models Human Use and Its Effect on Vaginal SHIV Acquisition Risk.

Authors:  Katherine Butler; Jana M Ritter; Shanon Ellis; Monica R Morris; Debra L Hanson; Janet M McNicholl; Ellen N Kersh
Journal:  J Acquir Immune Defic Syndr       Date:  2016-08-01       Impact factor: 3.731

2.  An accurate approximation for the expected site frequency spectrum in a Galton-Watson process under an infinite sites mutation model.

Authors:  John L Spouge
Journal:  Theor Popul Biol       Date:  2019-03-12       Impact factor: 1.570

3.  Combination Emtricitabine and Tenofovir Disoproxil Fumarate Prevents Vaginal Simian/Human Immunodeficiency Virus Infection in Macaques Harboring Chlamydia trachomatis and Trichomonas vaginalis.

Authors:  Jessica Radzio; Tara Henning; Leecresia Jenkins; Shanon Ellis; Carol Farshy; Christi Phillips; Angela Holder; Susan Kuklenyik; Chuong Dinh; Debra Hanson; Janet McNicholl; Walid Heneine; John Papp; Ellen N Kersh; J Gerardo García-Lerma
Journal:  J Infect Dis       Date:  2016-01-06       Impact factor: 5.226

4.  Vaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus Macaques.

Authors:  Kara Jensen; Rafiq Nabi; Koen K A Van Rompay; Spencer Robichaux; Jeffrey D Lifson; Michael Piatak; William R Jacobs; Glenn Fennelly; Don Canfield; Katie R Mollan; Michael G Hudgens; Michelle H Larsen; Angela M Amedee; Pamela A Kozlowski; Kristina De Paris
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

5.  Maternal HIV-1 Env Vaccination for Systemic and Breast Milk Immunity To Prevent Oral SHIV Acquisition in Infant Macaques.

Authors:  Joshua A Eudailey; Maria L Dennis; Morgan E Parker; Bonnie L Phillips; Tori N Huffman; Camden P Bay; Michael G Hudgens; Roger W Wiseman; Justin J Pollara; Genevieve G Fouda; Guido Ferrari; David J Pickup; Pamela A Kozlowski; Koen K A Van Rompay; Kristina De Paris; Sallie R Permar
Journal:  mSphere       Date:  2018-01-10       Impact factor: 4.389

6.  Mucosal Vaccination with Heterologous Viral Vectored Vaccine Targeting Subdominant SIV Accessory Antigens Strongly Inhibits Early Viral Replication.

Authors:  Huanbin Xu; Anne-Marie Andersson; Emeline Ragonnaud; Ditte Boilesen; Anders Tolver; Benjamin Anderschou Holbech Jensen; James L Blanchard; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Allan Randrup Thomsen; Jan Pravsgaard Christensen; Ronald S Veazey; Peter Johannes Holst
Journal:  EBioMedicine       Date:  2017-03-08       Impact factor: 8.143

7.  Estimating the basic reproduction number of a pathogen in a single host when only a single founder successfully infects.

Authors:  Vruj Patel; John L Spouge
Journal:  PLoS One       Date:  2020-01-10       Impact factor: 3.240

8.  Production of Mucosally Transmissible SHIV Challenge Stocks from HIV-1 Circulating Recombinant Form 01_AE env Sequences.

Authors:  Lawrence J Tartaglia; Hui-Wen Chang; Benjamin C Lee; Peter Abbink; David Ng'ang'a; Michael Boyd; Christy L Lavine; So-Yon Lim; Srisowmya Sanisetty; James B Whitney; Michael S Seaman; Morgane Rolland; Sodsai Tovanabutra; Jintanat Ananworanich; Merlin L Robb; Jerome H Kim; Nelson L Michael; Dan H Barouch
Journal:  PLoS Pathog       Date:  2016-02-05       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.